GlaxoSmithKline and Vir start phase 2/3 study for Covid-19 antibody drug

Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients who are at high risk of hospitalization. CNBC's Meg Tirrell reports.